The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Utilization of HSCT globally for myeloma
Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the analysis of the global state of hematopoietic stem cell transplantation (HSCT) for multiple myeloma (MM). This new analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplantation (WBMT) and the Global Burden of Disease (GBD) study indicates that although autologous HSCT rates have increased globally, there are marked disparities in usage between high versus low to middle income countries. Additionally, allogeneic HSCT rates remained stable in Europe but declined in North America. Dr Cowan reveals more work is needed to improve access to HSCT for MM globally, particularly in education and training. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
